메뉴 건너뛰기




Volumn 61, Issue 10, 2014, Pages 1754-1760

A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group

(13)  Horton, Terzah M a   Perentesis, John P b   Gamis, Alan S c   Alonzo, Todd A d,e   Gerbing, Robert B e   Ballard, Jennifer f   Adlard, Kathleen g   Howard, Dianna S h   Smith, Franklin O i   Jenkins, Gaye a   Kelder, Angelé j   Schuurhuis, Gerrit J j   Moscow, Jeffrey A f  


Author keywords

AML; AraC; Pediatric oncology; Relapse; Velcade

Indexed keywords

ANTHRACYCLINE; BORTEZOMIB; CYTARABINE; ETOPOSIDE; IDARUBICIN;

EID: 84908549208     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25117     Document Type: Article
Times cited : (40)

References (50)
  • 1
    • 84875981508 scopus 로고    scopus 로고
    • Role of ubiquitin ligases and the proteasome in oncogenesis: Novel targets for anticancer therapies
    • Micel LN, Tentler JJ, Smith PG, et al. Role of ubiquitin ligases and the proteasome in oncogenesis: Novel targets for anticancer therapies. J Clin Oncol 2013; 31:1231-1238.
    • (2013) J Clin Oncol , vol.31 , pp. 1231-1238
    • Micel, L.N.1    Tentler, J.J.2    Smith, P.G.3
  • 2
    • 84856373151 scopus 로고    scopus 로고
    • Proteasome inhibitors: An expanding army attacking a unique target
    • Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome inhibitors: An expanding army attacking a unique target. Chem Biol 2012; 19:99-115.
    • (2012) Chem Biol , vol.19 , pp. 99-115
    • Kisselev, A.F.1    van der Linden, W.A.2    Overkleeft, H.S.3
  • 3
    • 77955059029 scopus 로고    scopus 로고
    • Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia
    • Szczepanek J, Pogorzala M, Konatkowska B, et al. Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia. Anticancer Res 2010; 30:2119-2124.
    • (2010) Anticancer Res , vol.30 , pp. 2119-2124
    • Szczepanek, J.1    Pogorzala, M.2    Konatkowska, B.3
  • 4
    • 63849281664 scopus 로고    scopus 로고
    • The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
    • Bianchi G, Oliva L, Cascio P, et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 2009; 113:3040-3049.
    • (2009) Blood , vol.113 , pp. 3040-3049
    • Bianchi, G.1    Oliva, L.2    Cascio, P.3
  • 5
    • 0025115736 scopus 로고
    • Abnormally high expression of proteasomes in human leukemic cells
    • Kumatori A, Tanaka K, Inamura N, et al. Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci U S A 1990; 87:7071-7075.
    • (1990) Proc Natl Acad Sci U S A , vol.87 , pp. 7071-7075
    • Kumatori, A.1    Tanaka, K.2    Inamura, N.3
  • 6
    • 5644250621 scopus 로고    scopus 로고
    • A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
    • Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127:165-172.
    • (2004) Br J Haematol , vol.127 , pp. 165-172
    • Jagannath, S.1    Barlogie, B.2    Berenson, J.3
  • 7
    • 0037973279 scopus 로고    scopus 로고
    • A phase 2 study of bortezomib in relapsed, refractory myeloma
    • Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-2617.
    • (2003) N Engl J Med , vol.348 , pp. 2609-2617
    • Richardson, P.G.1    Barlogie, B.2    Berenson, J.3
  • 8
    • 20044376092 scopus 로고    scopus 로고
    • Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
    • O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23:676-684.
    • (2005) J Clin Oncol , vol.23 , pp. 676-684
    • O'Connor, O.A.1    Wright, J.2    Moskowitz, C.3
  • 9
    • 36849020943 scopus 로고    scopus 로고
    • Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program
    • Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50:37-45.
    • (2008) Pediatr Blood Cancer , vol.50 , pp. 37-45
    • Houghton, P.J.1    Morton, C.L.2    Kolb, E.A.3
  • 10
    • 40949128188 scopus 로고    scopus 로고
    • Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia
    • Attar EC, De Angelo DJ, Supko JG, et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res 2008; 14:1446-1454.
    • (2008) Clin Cancer Res , vol.14 , pp. 1446-1454
    • Attar, E.C.1    De Angelo, D.J.2    Supko, J.G.3
  • 11
    • 84875693885 scopus 로고    scopus 로고
    • Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (alliance) study 10502
    • Attar EC, Johnson JL, Amrein PC, et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (alliance) study 10502. J Clin Oncol 2012; 31:923-929.
    • (2012) J Clin Oncol , vol.31 , pp. 923-929
    • Attar, E.C.1    Johnson, J.L.2    Amrein, P.C.3
  • 12
    • 33646003521 scopus 로고    scopus 로고
    • Bortezomib interactions with chemotherapy agents in acute leukemia in vitro
    • Horton TM, Gannavarapu A, Blaney SM, et al. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol 2006; 58:13-23.
    • (2006) Cancer Chemother Pharmacol , vol.58 , pp. 13-23
    • Horton, T.M.1    Gannavarapu, A.2    Blaney, S.M.3
  • 13
    • 34248377893 scopus 로고    scopus 로고
    • Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status
    • Minderman H, Zhou Y, O'loughlin KL, et al. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. Cancer Chemother Pharmacol 2007; 60:245-255.
    • (2007) Cancer Chemother Pharmacol , vol.60 , pp. 245-255
    • Minderman, H.1    Zhou, Y.2    O'loughlin, K.L.3
  • 14
    • 0037059012 scopus 로고    scopus 로고
    • Preferential induction of apoptosis for primary human leukemic stem cells
    • Guzman ML, Swiderski CF, Howard DS, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A 2002; 99:16220-16225.
    • (2002) Proc Natl Acad Sci U S A , vol.99 , pp. 16220-16225
    • Guzman, M.L.1    Swiderski, C.F.2    Howard, D.S.3
  • 15
    • 77955108100 scopus 로고    scopus 로고
    • Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium
    • Messinger Y, Gaynon P, Raetz E, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer 2010; 55:254-259.
    • (2010) Pediatr Blood Cancer , vol.55 , pp. 254-259
    • Messinger, Y.1    Gaynon, P.2    Raetz, E.3
  • 16
    • 84864045203 scopus 로고    scopus 로고
    • Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
    • Messinger YH, Gaynon PS, Sposto R, et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Blood 2012; 120:285-290.
    • (2012) Blood , vol.120 , pp. 285-290
    • Messinger, Y.H.1    Gaynon, P.S.2    Sposto, R.3
  • 17
    • 2342622545 scopus 로고    scopus 로고
    • Considerations for targeting malignant stem cells in leukemia
    • Guzman ML, Jordan CT. Considerations for targeting malignant stem cells in leukemia. Cancer Control 2004; 11:97-104.
    • (2004) Cancer Control , vol.11 , pp. 97-104
    • Guzman, M.L.1    Jordan, C.T.2
  • 19
    • 3242754448 scopus 로고    scopus 로고
    • Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity
    • Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004; 5:738-743.
    • (2004) Nat Immunol , vol.5 , pp. 738-743
    • Hope, K.J.1    Jin, L.2    Dick, J.E.3
  • 20
    • 84861781478 scopus 로고    scopus 로고
    • Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance
    • Hoang VT, Zepeda-Moreno A, Ho AD. Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance. Biotechnol J 2012; 7:779-788.
    • (2012) Biotechnol J , vol.7 , pp. 779-788
    • Hoang, V.T.1    Zepeda-Moreno, A.2    Ho, A.D.3
  • 21
    • 80052468964 scopus 로고    scopus 로고
    • Stem cell gene expression programs influence clinical outcome in human leukemia
    • Eppert K, Takenaka K, Lechman ER, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011; 17:1086-1093.
    • (2011) Nat Med , vol.17 , pp. 1086-1093
    • Eppert, K.1    Takenaka, K.2    Lechman, E.R.3
  • 22
    • 84866099500 scopus 로고    scopus 로고
    • Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells
    • Ashton JM, Balys M, Neering SJ, et al. Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells. Cell Stem Cell 2012; 11:359-372.
    • (2012) Cell Stem Cell , vol.11 , pp. 359-372
    • Ashton, J.M.1    Balys, M.2    Neering, S.J.3
  • 23
    • 78650444882 scopus 로고    scopus 로고
    • Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia
    • Gentles AJ, Plevritis SK, Majeti R, et al. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 2010; 304:2706-2715.
    • (2010) JAMA , vol.304 , pp. 2706-2715
    • Gentles, A.J.1    Plevritis, S.K.2    Majeti, R.3
  • 24
    • 84865183566 scopus 로고    scopus 로고
    • Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS
    • Barreyro L, Will B, Bartholdy B, et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 2012; 120:1290-1298.
    • (2012) Blood , vol.120 , pp. 1290-1298
    • Barreyro, L.1    Will, B.2    Bartholdy, B.3
  • 25
    • 79952092993 scopus 로고    scopus 로고
    • Leukemia stem cells and microenvironment: Biology and therapeutic targeting
    • Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: Biology and therapeutic targeting. J Clin Oncol 2011; 29:591-599.
    • (2011) J Clin Oncol , vol.29 , pp. 591-599
    • Konopleva, M.Y.1    Jordan, C.T.2
  • 26
    • 25144433295 scopus 로고    scopus 로고
    • High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival
    • van Rhenen A, Feller N, Kelder A, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005; 11:6520-6527.
    • (2005) Clin Cancer Res , vol.11 , pp. 6520-6527
    • van Rhenen, A.1    Feller, N.2    Kelder, A.3
  • 27
    • 31544436322 scopus 로고    scopus 로고
    • AML engraftment in the NOD/SCID assay reflects the outcome of AML: Implications for our understanding of the heterogeneity of AML
    • Pearce DJ, Taussig D, Zibara K, et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: Implications for our understanding of the heterogeneity of AML. Blood 2006; 107:1166-1173.
    • (2006) Blood , vol.107 , pp. 1166-1173
    • Pearce, D.J.1    Taussig, D.2    Zibara, K.3
  • 28
    • 16544389047 scopus 로고    scopus 로고
    • Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: A Children's Oncology Group Study (ADVL0015)
    • Blaney SM, Bernstein M, Neville K, et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: A Children's Oncology Group Study (ADVL0015). J Clin Oncol 2004; 22:4752-4757.
    • (2004) J Clin Oncol , vol.22 , pp. 4752-4757
    • Blaney, S.M.1    Bernstein, M.2    Neville, K.3
  • 29
    • 33947362982 scopus 로고    scopus 로고
    • A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: A Children's Oncology Group Study
    • Horton TM, Pati D, Plon SE, et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: A Children's Oncology Group Study. Clin Cancer Res 2007; 13:1516-1522.
    • (2007) Clin Cancer Res , vol.13 , pp. 1516-1522
    • Horton, T.M.1    Pati, D.2    Plon, S.E.3
  • 30
    • 84876454133 scopus 로고    scopus 로고
    • A phase II study of bortezomib with ifosfamide and vinorelbine in pediatric patients with refractory/recurrent Hodgkin disease (HD): A Children's Oncology Group (COG) Study [abstract]
    • Horton TM, Drachtman RA, Chen L, et al. A phase II study of bortezomib with ifosfamide and vinorelbine in pediatric patients with refractory/recurrent Hodgkin disease (HD): A Children's Oncology Group (COG) Study [abstract]. Proc ASCO 2010; 28:9537.
    • (2010) Proc ASCO , vol.28 , pp. 9537
    • Horton, T.M.1    Drachtman, R.A.2    Chen, L.3
  • 31
    • 1542753559 scopus 로고    scopus 로고
    • Revised recommendations of the International Working Group for Diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
    • Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21:4642-4649.
    • (2003) J Clin Oncol , vol.21 , pp. 4642-4649
    • Cheson, B.D.1    Bennett, J.M.2    Kopecky, K.J.3
  • 32
    • 84868129082 scopus 로고    scopus 로고
    • Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel
    • Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel. Blood 2012; 120:3187-3205.
    • (2012) Blood , vol.120 , pp. 3187-3205
    • Creutzig, U.1    van den Heuvel-Eibrink, M.M.2    Gibson, B.3
  • 33
    • 0029591692 scopus 로고
    • Incorporating toxicity considerations into the design of two-stage phase II clinical trials
    • Bryant J, Day R. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 1995; 51:1372-1383.
    • (1995) Biometrics , vol.51 , pp. 1372-1383
    • Bryant, J.1    Day, R.2
  • 34
    • 0042386631 scopus 로고    scopus 로고
    • Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951
    • Wells RJ, Adams MT, Alonzo TA, et al. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. J Clin Oncol 2003; 21:2940-2947.
    • (2003) J Clin Oncol , vol.21 , pp. 2940-2947
    • Wells, R.J.1    Adams, M.T.2    Alonzo, T.A.3
  • 35
    • 84878230614 scopus 로고    scopus 로고
    • Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): A report from the Children's Oncology Group
    • Cooper TM, Razzouk BI, Gerbing R, et al. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): A report from the Children's Oncology Group. Pediatr Blood Cancer 2013; 60:1141-1147.
    • (2013) Pediatr Blood Cancer , vol.60 , pp. 1141-1147
    • Cooper, T.M.1    Razzouk, B.I.2    Gerbing, R.3
  • 36
    • 49249109608 scopus 로고    scopus 로고
    • Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: A Children's Oncology Group Pilot Study
    • Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: A Children's Oncology Group Pilot Study. J Clin Oncol 2008; 26:3756-3762.
    • (2008) J Clin Oncol , vol.26 , pp. 3756-3762
    • Raetz, E.A.1    Cairo, M.S.2    Borowitz, M.J.3
  • 37
    • 84875423224 scopus 로고    scopus 로고
    • Improved outcome in pediatric relapsed acute myeloid leukemia: Results of a randomized trial on liposomal daunorubicin by the International BFM Study Group
    • Kaspers GJ, Zimmermann M, Reinhardt D, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: Results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol 2013; 31:599-607.
    • (2013) J Clin Oncol , vol.31 , pp. 599-607
    • Kaspers, G.J.1    Zimmermann, M.2    Reinhardt, D.3
  • 38
    • 84906052001 scopus 로고    scopus 로고
    • How I treat pediatric relapsed acute myeloid leukemia
    • DOI: 10.1111/bjh.12947. [Epub ahead of print]
    • Kaspers G. How I treat pediatric relapsed acute myeloid leukemia. Br J Haematol. DOI: 10.1111/bjh.12947. [Epub ahead of print]
    • Br J Haematol.
    • Kaspers, G.1
  • 39
    • 33645292701 scopus 로고    scopus 로고
    • Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma
    • Miyakoshi S, Kami M, Yuji K, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006; 107:3492-3494.
    • (2006) Blood , vol.107 , pp. 3492-3494
    • Miyakoshi, S.1    Kami, M.2    Yuji, K.3
  • 40
    • 34247207092 scopus 로고    scopus 로고
    • Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone
    • Chew E, Filshie R, Wei A. Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone. Leuk Lymphoma 2007; 48:212-213.
    • (2007) Leuk Lymphoma , vol.48 , pp. 212-213
    • Chew, E.1    Filshie, R.2    Wei, A.3
  • 41
    • 38949185746 scopus 로고    scopus 로고
    • Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: A report from the children's oncology group
    • Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: A report from the children's oncology group. Blood 2008; 111:1044-1053.
    • (2008) Blood , vol.111 , pp. 1044-1053
    • Lange, B.J.1    Smith, F.O.2    Feusner, J.3
  • 42
    • 84872470330 scopus 로고    scopus 로고
    • A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916)
    • Muscal JA, Thompson PA, Horton TM, et al. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916). Pediatr Blood Cancer 2013; 60:390-395.
    • (2013) Pediatr Blood Cancer , vol.60 , pp. 390-395
    • Muscal, J.A.1    Thompson, P.A.2    Horton, T.M.3
  • 43
    • 84893858504 scopus 로고    scopus 로고
    • Positive feedback between NF-kappaB and TNF-alpha promotes leukemia-initiating cell capacity
    • Kagoya Y, Yoshimi A, Kataoka K, et al. Positive feedback between NF-kappaB and TNF-alpha promotes leukemia-initiating cell capacity. J Clin Invest 2014; 124:528-542.
    • (2014) J Clin Invest , vol.124 , pp. 528-542
    • Kagoya, Y.1    Yoshimi, A.2    Kataoka, K.3
  • 44
    • 84902103433 scopus 로고    scopus 로고
    • Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia
    • Koyama D, Kikuchi J, Hiraoka N, et al. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. Leukemia 2013; 28:1216-1226.
    • (2013) Leukemia , vol.28 , pp. 1216-1226
    • Koyama, D.1    Kikuchi, J.2    Hiraoka, N.3
  • 45
    • 84884682737 scopus 로고    scopus 로고
    • Protein kinase CK2 inhibition down modulates the NF-kappaB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells
    • Manni S, Brancalion A, Mandato E, et al. Protein kinase CK2 inhibition down modulates the NF-kappaB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells. PLoS ONE 2013; 8:e75280.
    • (2013) PLoS ONE , vol.8
    • Manni, S.1    Brancalion, A.2    Mandato, E.3
  • 46
    • 84879873870 scopus 로고    scopus 로고
    • Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors
    • Tagoug I, Jordheim LP, Herveau S, et al. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors. Clin Cancer Res 2013; 19:3556-33566.
    • (2013) Clin Cancer Res , vol.19 , pp. 3556-33566
    • Tagoug, I.1    Jordheim, L.P.2    Herveau, S.3
  • 47
    • 84875192633 scopus 로고    scopus 로고
    • Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-kappaB
    • Bastian L, Hof J, Pfau M, et al. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-kappaB. Clin Cancer Res 2013; 19:1445-1457.
    • (2013) Clin Cancer Res , vol.19 , pp. 1445-1457
    • Bastian, L.1    Hof, J.2    Pfau, M.3
  • 48
    • 78650950098 scopus 로고    scopus 로고
    • Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammac-deficient mice
    • Sarry JE, Murphy K, Perry R, et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammac-deficient mice. J Clin Invest 2011; 121:384-395.
    • (2011) J Clin Invest , vol.121 , pp. 384-395
    • Sarry, J.E.1    Murphy, K.2    Perry, R.3
  • 49
    • 34948839959 scopus 로고    scopus 로고
    • The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells
    • van Rhenen A, van Dongen GA, Kelder A, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 2007; 110:2659-2666.
    • (2007) Blood , vol.110 , pp. 2659-2666
    • van Rhenen, A.1    van Dongen, G.A.2    Kelder, A.3
  • 50
    • 0035886024 scopus 로고    scopus 로고
    • Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells
    • Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98:2301-2307.
    • (2001) Blood , vol.98 , pp. 2301-2307
    • Guzman, M.L.1    Neering, S.J.2    Upchurch, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.